ArticleJournal of ovarian research2025
Salvia miltiorrhiza extract ameliorated ovarian damage induced by cyclophosphamide in mice by multidimensional mechanisms.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ROS: their roles in diminished ovarian reserve.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionCyclophosphamide (CTX) can result in particularly severe ovarian damage by the broad range of damaging mechanisms, yet now single compounds struggle to provide comprehensive protection against CTX-induced ovarian damage. Salviae Miltiorrhizae Radix et Rhizoma (SM), as the traditional Chinese medicines (TCMs) with multi-component nature, offers hope for prevention and treatment against multi-mechanistic drugs causing ovarian damage. In this study, we aimed to investigate the protective effect of SM on ovarian hypofunction induced by CTX and explore its underlying mechanisms in mice.
methodsThe Salvia miltiorrhiza Bunge with a final concentration of 1.33 g/mL was administrated daily by gavage in mice with tumor xenografts and/or CTX intraperitoneal intervention. The subcutaneous xenograft tumor volume of each mouse was recorded and calculated every 3 days by measuring its width and length. After drug administration, estrous cycle was monitored and follicle counting was performed by H&E staining, as well as ELISA assays for serum hormone and mating experiment for fertility assessment. The apoptosis inhibition, antioxidant capacity, vascular protective and anti-fibrotic effects of SM was respectively evaluated by TUNEL staining, ROS, DPPH scavenging and antioxidant enzymes assays, vascular morphological observation, masson staining, as well as immunofluorescence staining and western blotting for the related-protein expression.
resultsSM didn't affect the anti-cancer efficacy of CTX and tumor growth rate in vivo. After SM administration for 41 days, the dropped body weight and decreased ovarian index caused by CTX gained obviously, the disturbed estrus cycle was markedly restored, a significant increase emerged in the levels of AMH and E
conclusionOur findings verified that SM could significantly reduce primordial follicle (PMF) loss and follicular atresia, and ameliorate CTX-induced ovarian dysfunction and poor fertility, but didn't affect the anti-tumor effect of CTX and tumor growth. Further compelling evidence was provided that, the protective effect of SM may be related to apoptosis inhibition, low oxidative stress, vascular protection and anti-fibrotic effect, which further confirmed the comprehensive protection of SM on CTX-induced ovarian damage, thereby supporting its potential clinical efficacy in mitigating chemotherapy-induced decline of ovarian function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.